Skip to main content
Premium Trial:

Request an Annual Quote

Undisclosed Pharma to Evaluate Silence siRNA-Delivery Technology

Premium

Silence Therapeutics this week announced that it has signed a deal under which one of its proprietary siRNA delivery technologies will be evaluated by an undisclosed “global pharmaceutical” company.

Specifically, Silence will formulate siRNAs provided by the pharmaceutical firm with its its drug-assembling cholesterol complex, or DACC, technology for intravenous delivery into the pulmonary vascular endothelium.

Both companies will undertake in vitro and in vivo studies of the siRNAs and select lead candidates for further development. Additional terms of the arrangement were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.